Literature DB >> 33740930

Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level.

Qianqian Yuan1, Jinxuan Hou1, Yukun He1, Yiqian Liao1, Lewei Zheng1, Gaosong Wu2.   

Abstract

BACKGROUND: Breast cancer-related lymphedema (BCRL) is associated with extensive axillary dissection. Axillary lymph node dissection (ALND) based on breast lymphatics level (BLL) was proposed to minimize the surgical extent for node-positive breast cancer patients.
METHODS: A total of 156 consecutive sentinel lymph node-positive (SLN+) or clinically node-positive (cN+) patients underwent sentinel lymph node biopsy (SLNB) with indocyanine green and methylene blue (MB). The SLNs were injected with 0.1 ml MB before removal, and a standard ALND was subsequently performed. The nodes adjacent to the blue-stained axillary lymph nodes from the breast (bALNs) were sent for pathological examination separately by resecting serial tissue every 0.5 cm away from the marginal blue-stained bALNs. Then, a pilot study comparing ALND based on BLL and standard ALND was performed.
RESULTS: BLL were successfully identified in 20 SLN+ (100%) and 134 cN+ (98.5%) patients. The median number of BLL was four, ranging from three to six. A horizontal line 1.0 cm away from the superior blue-stained bALN and a vertical line 1.0 cm away from the medial blue-stained bALN formed BLL II, III, and IV. All of the additional positive nodes were within 1.0 cm of the blue-stained bALNs. The minimized axillary dissection should resect upwards from the lowest BLL that contains the first confirmed negative blue-stained bALNs. In the pilot study, no patient developed axillary recurrence.
CONCLUSION: The ALND surgical procedure based on BLL could minimize the surgical extent for pathological node-positive breast cancer patients and potentially reduce the BCRL rate. TRIAL REGISTRATION: ChiCTR1800014247 .

Entities:  

Keywords:  Axillary lymph node dissection; Breast cancer; Breast cancer related lymphedema

Mesh:

Substances:

Year:  2021        PMID: 33740930      PMCID: PMC7980601          DOI: 10.1186/s12885-021-08024-y

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  23 in total

Review 1.  Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.

Authors:  Tracey DiSipio; Sheree Rye; Beth Newman; Sandi Hayes
Journal:  Lancet Oncol       Date:  2013-03-27       Impact factor: 41.316

2.  Surgical Management of the Axilla in Breast Cancer Patients with Negative Sentinel Lymph Node: A Method to Reduce False-Negative Rate.

Authors:  Qianqian Yuan; Gaosong Wu; Shu-Yuan Xiao; Yukun He; Kun Wang; Dan Zhang
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

3.  Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.

Authors:  Ingrid G M Poodt; Pauline E R Spronk; Guusje Vugts; Thijs van Dalen; M T F D Vrancken Peeters; Marjolijn L Rots; Anne Kuijer; Grard A P Nieuwenhuijzen; Robert-Jan Schipper
Journal:  Ann Surg       Date:  2018-12       Impact factor: 12.969

4.  Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer.

Authors:  Robert C G Martin; Anees Chagpar; Charles R Scoggins; Michael J Edwards; Lee Hagendoorn; Arnold J Stromberg; Kelly M McMasters
Journal:  Ann Surg       Date:  2005-06       Impact factor: 12.969

5.  Identification and Preservation of Arm Lymphatic System in Axillary Dissection for Breast Cancer to Reduce Arm Lymphedema Events: A Randomized Clinical Trial.

Authors:  Qianqian Yuan; Gaosong Wu; Shu-Yuan Xiao; Jinxuan Hou; Yuqi Ren; Hongying Wang; Kun Wang; Dan Zhang
Journal:  Ann Surg Oncol       Date:  2019-06-25       Impact factor: 5.344

Review 6.  Management of the axilla in women with breast cancer.

Authors:  John R Benson; G Querci della Rovere
Journal:  Lancet Oncol       Date:  2007-04       Impact factor: 41.316

7.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Authors:  Armando E Giuliano; Karla V Ballman; Linda McCall; Peter D Beitsch; Meghan B Brennan; Pond R Kelemen; David W Ollila; Nora M Hansen; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow
Journal:  JAMA       Date:  2017-09-12       Impact factor: 56.272

8.  Intraoperative detection of sentinel lymph nodes in breast cancer patients using ultrasonography-guided direct indocyanine green dye-marking by real-time virtual sonography constructed with three-dimensional computed tomography-lymphography.

Authors:  Shigeru Yamamoto; Noriko Maeda; Kiyoshi Yoshimura; Masaaki Oka
Journal:  Breast       Date:  2013-05-29       Impact factor: 4.380

9.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.

Authors:  Abigail S Caudle; Wei T Yang; Savitri Krishnamurthy; Elizabeth A Mittendorf; Dalliah M Black; Michael Z Gilcrease; Isabelle Bedrosian; Brian P Hobbs; Sarah M DeSnyder; Rosa F Hwang; Beatriz E Adrada; Simona F Shaitelman; Mariana Chavez-MacGregor; Benjamin D Smith; Rosalind P Candelaria; Gildy V Babiera; Basak E Dogan; Lumarie Santiago; Kelly K Hunt; Henry M Kuerer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection.

Authors:  Claude Nos; Benedicte Lesieur; Krishna B Clough; Fabrice Lecuru
Journal:  Ann Surg Oncol       Date:  2007-06-05       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.